Accelerating Medicines Partnership - Alzheimer's Disease
The Accelerating Medicines Partnership Alzheimer’s Disease Project (AMP-AD) is a precompetitive partnership among government, industry, and nonprofit organizations that focuses on discovering novel, clinically relevant therapeutic targets and on developing biomarkers to help validate existing therapeutic targets.
Visit fnih.org/amp-ad to learn more.
Видео Accelerating Medicines Partnership - Alzheimer's Disease канала FNIH
Visit fnih.org/amp-ad to learn more.
Видео Accelerating Medicines Partnership - Alzheimer's Disease канала FNIH
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
FNIH highlights success of the ABC-CT program in advancing neuropsychiatric biomarkers for autism2015 Year in ReviewDr Ruslan M Medzhitov Wins 2013 Lurie Prize in Biomedical SciencesDr. Jeannie T. Lee's Scientific Research in Epigenetic RegulationNBC 4 Report: I-SPY 2 Clinical TrialExpert Talk with 2022 Lurie Prize recipients Anne Brunet, PhD, and Andrew Dillin, PhDEffector Function Seminar Series: Mouse models of effector function/FcR & IgG allotype polymorphismsVision for AMP HF - Dr. Sanjiv ShahAbout 2021 Lurie Prize Recipient Dr. Xiaowei ZhuangCharles A. Sanders, M.D., Scientific SymposiumEffector Function Seminar Series: Convalescent plasma correlates of protectionThe 22nd Annual Norman P. Salzman Memorial Awards and Symposium in Basic and Clinical VirologyFNIH AMP RA/Lupus Patient PerspectiveExpert Talk with Dr. Xiaowei ZhuangNon-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE)The Quiet Leaders of COVID: Shaping The Future Of Science2020 Lurie Prize Recipient Aviv Regev, Ph.D. Research07_Beyond P-Values_ Computing the Probability of a True Association06_An Empirical Approach to Null Hypothesis Testing2019 FNIH Biomarkers Consortium Neuroscience Symposium Session 3 - Imaging Biomarkers